Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Baxter
Boehringer Ingelheim
Colorcon
McKinsey
Express Scripts
Dow

Last Updated: January 20, 2020

DrugPatentWatch Database Preview

Details for Patent: 8,481,598

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

Which drugs does patent 8,481,598 protect, and when does it expire?

Patent 8,481,598 protects FETZIMA and is included in one NDA.

This patent has eight patent family members in four countries.

Summary for Patent: 8,481,598
Title:Stable dosage forms of levomilnacipran
Abstract: The present invention relates to stable dosage forms of levomilnacipran and pharmaceutically acceptable salts thereof. Processes for the preparation of these dosage forms and methods of using these dosage forms are also described.
Inventor(s): Surana; Rahul (Commack, NY), Divi; Murali (Ronkonkoma, NY), Chhettry; Anil (Holtsville, NY)
Assignee:
Application Number:13/006,993
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 8,481,598
Patent Claim Types:
see list of patent claims
Use; Dosage form;

Drugs Protected by US Patent 8,481,598

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Allergan FETZIMA levomilnacipran hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 204168-001 Jul 25, 2013 RX Yes No   Start Trial   Start Trial TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)   Start Trial
Allergan FETZIMA levomilnacipran hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 204168-002 Jul 25, 2013 RX Yes No   Start Trial   Start Trial TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)   Start Trial
Allergan FETZIMA levomilnacipran hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 204168-003 Jul 25, 2013 RX Yes No   Start Trial   Start Trial TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)   Start Trial
Allergan FETZIMA levomilnacipran hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 204168-004 Jul 25, 2013 RX Yes Yes   Start Trial   Start Trial TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 8,481,598

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Canada 2779711   Start Trial
Canada 2790933   Start Trial
European Patent Office 2496079   Start Trial
European Patent Office 2536688   Start Trial
Japan 2013510176   Start Trial
Japan 2013517290   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
AstraZeneca
Medtronic
McKinsey
Colorcon
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.